156 related articles for article (PubMed ID: 35624169)
1. Public support in the United States for global equity in vaccine pricing.
Chan Y; Datt G; Islam A; Rai B; Wang LC
Sci Rep; 2022 May; 12(1):8960. PubMed ID: 35624169
[TBL] [Abstract][Full Text] [Related]
2. Tiered Pricing and Alternative Mechanisms for Equitative Access to Vaccines in Latin America: A Narrative Review of the Literature.
Arango-Luque A; Yucumá D; Castañeda CE; Espin J; Becerra-Posada F
Value Health Reg Issues; 2024 Jul; 42():100981. PubMed ID: 38677063
[TBL] [Abstract][Full Text] [Related]
3. Analytics for vaccine economics and pricing: insights and observations.
Robbins MJ; Jacobson SH
Expert Rev Vaccines; 2015 Apr; 14(4):605-16. PubMed ID: 25435003
[TBL] [Abstract][Full Text] [Related]
4. Access to medicines and hepatitis C in Africa: can tiered pricing and voluntary licencing assure universal access, health equity and fairness?
Assefa Y; Hill PS; Ulikpan A; Williams OD
Global Health; 2017 Sep; 13(1):73. PubMed ID: 28903757
[TBL] [Abstract][Full Text] [Related]
5. Consideration Of Value-Based Pricing For Treatments And Vaccines Is Important, Even In The COVID-19 Pandemic.
Neumann PJ; Cohen JT; Kim DD; Ollendorf DA
Health Aff (Millwood); 2021 Jan; 40(1):53-61. PubMed ID: 33211534
[TBL] [Abstract][Full Text] [Related]
6. Differential pricing for pharmaceuticals: reconciling access, R&D and patents.
Danzon PM; Towse A
Int J Health Care Finance Econ; 2003 Sep; 3(3):183-205. PubMed ID: 14625999
[TBL] [Abstract][Full Text] [Related]
7. International Reference Pricing for Prescription Drugs in the United States: Administrative Limitations and Collateral Effects.
Rand LZ; Kesselheim AS
Value Health; 2021 Apr; 24(4):473-476. PubMed ID: 33840424
[TBL] [Abstract][Full Text] [Related]
8. Vaccine Prices: A Systematic Review of Literature.
Hussain R; Bukhari NI; Ur Rehman A; Hassali MA; Babar ZU
Vaccines (Basel); 2020 Oct; 8(4):. PubMed ID: 33137948
[TBL] [Abstract][Full Text] [Related]
9. [Mechanics and effects of European reference pricing for vaccines in Germany according to §130a Abs. 2 SGB V: an analysis using the example of influenza vaccines].
Barth J; Hammerschmidt T; Vollmar J; Bierbaum M; Schöffski O
Gesundheitswesen; 2014 Apr; 76(4):e7-e13. PubMed ID: 24081570
[TBL] [Abstract][Full Text] [Related]
10. Enhancing affordability and profit in a non-cooperative, coordinated, hypothetical pediatric vaccine market via sequential optimization.
Alves-Maciel B; Proano RA
Health Care Manag Sci; 2024 Jun; ():. PubMed ID: 38951318
[TBL] [Abstract][Full Text] [Related]
11. Comparative value-based pricing of an Ebola vaccine in resource-constrained countries based on cost-effectiveness analysis.
Obeng-Kusi M; Erstad B; Roe DJ; Abraham I
J Med Econ; 2022; 25(1):894-902. PubMed ID: 35748085
[TBL] [Abstract][Full Text] [Related]
12. Pricing of new vaccines.
Lee BY; McGlone SM
Hum Vaccin; 2010 Aug; 6(8):619-26. PubMed ID: 20861678
[TBL] [Abstract][Full Text] [Related]
13. Vaccine purchasing groups in the United States: An overview of their policies and practices.
Cowan AE; Clark SJ; Gordon JL; Bok K; Shen AK
Vaccine; 2016 Sep; 34(42):5060-5065. PubMed ID: 27614782
[TBL] [Abstract][Full Text] [Related]
14. A Call to Action Against Persistent Lack of Transparency in Vaccine Pricing Practices During the COVID-19 Pandemic.
Arguedas-Ramírez G
Ann Glob Health; 2022; 88(1):87. PubMed ID: 36311897
[TBL] [Abstract][Full Text] [Related]
15. Tiered pricing of vaccines: a win-win-win situation, not a subsidy.
Plahte J
Lancet Infect Dis; 2005 Jan; 5(1):58-63. PubMed ID: 15620562
[TBL] [Abstract][Full Text] [Related]
16. A cost analysis of producing vaccines in developing countries.
Munira SL; Hendriks JT; Atmosukarto II; Friede MH; Carter LM; Butler JRG; Clements ACA
Vaccine; 2019 Feb; 37(9):1245-1251. PubMed ID: 30651198
[TBL] [Abstract][Full Text] [Related]
17. Pricing the COVID-19 vaccine: A mathematical approach.
Martonosi SE; Behzad B; Cummings K
Omega; 2021 Sep; 103():102451. PubMed ID: 33785979
[TBL] [Abstract][Full Text] [Related]
18. Pricing strategies for combination pediatric vaccines based on the lowest overall cost formulary.
Behzad B; Jacobson SH; Sewell EC
Expert Rev Vaccines; 2012 Oct; 11(10):1189-97. PubMed ID: 23176652
[TBL] [Abstract][Full Text] [Related]
19. Current Global Pricing For Human Papillomavirus Vaccines Brings The Greatest Economic Benefits To Rich Countries.
Herlihy N; Hutubessy R; Jit M
Health Aff (Millwood); 2016 Feb; 35(2):227-34. PubMed ID: 26858374
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
